World Library  
Flag as Inappropriate
Email this Article

Turosteride

Article Id: WHEBN0026849255
Reproduction Date:

Title: Turosteride  
Author: World Heritage Encyclopedia
Language: English
Subject: Epristeride, Galeterone, Abiraterone acetate, Cyproterone acetate, Anabolic steroid
Collection: 5-Alpha-Reductase Inhibitors, Lactams, Ureas
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Turosteride

Turosteride
Systematic (IUPAC) name
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-1,4a,6a-trimethyl-2-oxo-N-(propan-2-yl)-N-(propan-2-ylcarbamoyl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Clinical data
Legal status
  • Never marketed
Routes Oral
Identifiers
CAS number
ATC code None
PubChem
ChemSpider
UNII  YesY
Synonyms 1-(4-methyl-3-oxo-4-aza-5-alpha-androstane-17-beta-carbonyl)-1,3- diisopropylurea
Chemical data
Formula C27H45N3O3 
Mol. mass 459.66 g/mol

Turosteride (FCE-26,073) is a selective inhibitor of the enzyme 5α-reductase which was under investigation by GlaxoSmithKline for the treatment of benign prostatic hyperplasia (BPH), but was never marketed.[1][2][3] Similarly to finasteride, turosteride is selective for the type II isoform of 5α-redcutase, with about 15-fold selectivity for it over type I isoform of the enzyme.[4][5] In animal studies it has been shown to inhibit prostate size and retard tumor growth.[2][3][6][7] It may also be useful for the treatment of acne and hair loss.[8][9][10]

See also

References

  1. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC.  
  2. ^ a b di Salle E, Giudici D, Briatico G, Ornati G, Panzeri A (November 1993). "Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat". The Journal of Steroid Biochemistry and Molecular Biology 46 (5): 549–55.  
  3. ^ a b Di Salle E, Briatico G, Giudici D, Ornati G, Panzeri A (February 1994). "Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073)". The Journal of Steroid Biochemistry and Molecular Biology 48 (2-3): 241–8.  
  4. ^ Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM (September 1995). "Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors". The Journal of Steroid Biochemistry and Molecular Biology 54 (5-6): 273–9.  
  5. ^ Seiffert K, Seltmann H, Fritsch M, Zouboulis CC (February 2007). "Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro". Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme 39 (2): 141–8.  
  6. ^ Zaccheo T, Giudici D, di Salle E (February 1997). "Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma". The Prostate 30 (2): 85–91.  
  7. ^ Zaccheo T, Giudici D, di Salle E (June 1998). "Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats". The Prostate 35 (4): 237–42.  
  8. ^ Rawlings, Anthony V.; Webster, Guy F. (2007). Acne and its therapy. New York: Informa Healthcare USA.  
  9. ^ "Hairloss Treatment: Turosteride". 
  10. ^ "Hair Loss Drugs - Turosteride - competitive and specific inhibitor of Type II 5a-reductase. - Database of Drugs for Hair Loss". 


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.